Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 30:9:2786.
doi: 10.3389/fimmu.2018.02786. eCollection 2018.

Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target

Affiliations
Review

Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target

Claudia Buerger. Front Immunol. .

Abstract

Although modern biologics targeting different inflammatory mediators show promising therapeutic success, comprehensive knowledge about the molecular events in psoriatic keratinocytes that contribute to the pathogenesis and could serve as therapeutic targets is still scarce. However, recent efforts to understand the deregulated signal transduction pathways have led to the development of small molecule inhibitors e.g., tofacitinib targeting the Jak/Stat cascade that opens additional therapeutic options. Recently, the PI3-K/Akt/mTOR signaling pathway has emerged as an important player in the control of epidermal homeostasis. This review summarizes the current knowledge on the role of this pathway in the pathogenesis of psoriasis, especially the epidermal manifestation of the disease and discusses current approaches to target the pathway therapeutically.

Keywords: keratinocytes; mTORC1; psoriasis; rapamycin; topical agent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The PI3-K/Akt/mTOR signaling cascade. Stimulation of receptor tyrosine kinases (RTK) and G-protein-coupled receptors (GPCR) leads to activation of PI3-K, which then synthesizes PIP3 in the membrane. Subsequently, Akt is recruited to the membrane and phosphorylated by PDK-1 and mTORC2. The activated Akt kinase phosphorylates various substrates such as PRAS40, which is then inactivated and releases mTORC1. In addition, TSC2 is inhibited so that the downstream GTPase Rheb remains GTP-bound and can activate mTORC1. The fully activated mTORC1 complex then activates proteins of the translation machinery by phosphorylating S6K-1 or 4E-BP1 [adapted from Manning et al. 23).
Figure 2
Figure 2
Model, how mTORC1 signaling controls epidermal homeostasis and contributes to psoriasis. In healthy, basal keratinocytes, mTORC1 signaling pathway is active and controls proliferation while blocking differentiation. When cells leave the proliferative, basal compartment, mTORC1 is switched off and differentiation is enabled. Under inflammatory conditions, such as in psoriasis, mTORC1 is permanently activated, which leads to massive proliferation in the basal layer and disturbed keratinocyte differentiation in suprabasal layers, resulting in the phenotypic changes typical of psoriasis.

References

    1. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. (2018) 9:579. 10.3389/fimmu.2018.00579 - DOI - PMC - PubMed
    1. Boehncke WH, Schon MP. Psoriasis. Lancet (2015) 386:983–94. 10.1016/S0140-6736(14)61909-7 - DOI - PubMed
    1. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. . Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 449:564–9. 10.1038/nature06116 - DOI - PubMed
    1. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. . Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. (2009) 129:79–88. 10.1038/jid.2008.194 - DOI - PMC - PubMed
    1. Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol. (2017) 55:295–311 10.1007/s12016-017-8634-3 - DOI - PubMed

Publication types

Substances